Abstract. The aim of the present study was to investigate the protein expression of DNA methyltransferases (DNMTs) and genomic DNA methylation status of genomes in gastric signet ring cell carcinoma (SRC). Immunohistochemistry was performed to analyze DNMT expression and methylated DNA immunoprecipitation microarray (MeDIP-chip) and MeDIP quantitative real-time PCR (MeDIP-qPCR) were performed to analyze the genomic DNA methylation status in gastric SRC tissue. An increase in DNMT1 and decrease in DNMT3A expression in SRC tissue was observed compared with matched non-cancerous tissue. However, expression of other DNMTs, DNMT2, DNMT3B and DNMT3L, was not found to differ significantly between carcinoma and control. The MeDIP-chip assay revealed that methylation of gene promoters and CpG islands in SRC was higher than those in matched control tissue. However, MeDIP-qPCR analysis demonstrated that specific tumor-related genes, including ABL2, FGF18, TRAF2, EGFL7 and RAB33A were aberrantly hypomethylated in SRC tissue. Results of the current study indicate that gastric SRC may produce complex patterns of aberrant DNA methylation and DNMT expression.
Introduction
Epigenetics is the study of inherited genetic changes that occur without altering the DNA sequence. DNA methylation is a mechanism of epigenetic change, with the most widely studied epigenetic alteration in human tumor cells being histone modification and chromatin remodeling (1) . Human tumor cells exhibit aberrant DNA methylation patterns, including the hypermethylation of CpG islands in tumor suppressor genes (TSGs) and a global loss of DNA methylation in the genome (2) . These changes are associated with the inactivation of TSGs and the activation of oncogenes or tumor promoter genes (TPGs), and may promote tumor progression (3) . Abnormal expression of DNA methyltransferase (DNMT) may be important in the aberrant DNA methylation that occurs in tumors (4) . Previous studies have identified elevated DNMT expression in tumors when compared with control tissue (5) (6) (7) (8) and the overexpression of DNMT may contribute to tumor progression through the hypermethylation-mediated inactivation of TSGs in CpG islands (9) . In the current study, expression of DNMTs (DNMT1, DNMT2, DNMT3A, DNMT3B and DNMT3L) and the DNA methylation pattern of the genome in gastric signet ring cell carcinoma (SRC) was investigated. Results of this study are likely to aid future epigenetic studies investigating SRC.
Materials and methods
Ethics statement. All experimental procedures were approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (Chongqing, China). All patients provided written informed consent.
Clinical specimens. Twenty-eight pairs of human gastric SRC and matched non-cancerous tissue specimens (gastric mucosa tissue located >5 cm from cancerous areas) were obtained from the Department of General Surgery of the First Affiliated Hospital of Chongqing Medical University. Characteristics of these tissues are presented in Table I . Tissues were fixed in formalin and embedded in paraffin for immunohistochemistry testing, and their diagnosis was confirmed by pathological analysis. For the methylated DNA immunoprecipitation microarray (MeDIP-chip) assay, one pair of gastric tissues was selected for pathological examination to verify that the selected cancerous and matched non-cancerous tissue specimens consisted of >95% cancer and mucosal cells, respectively. In addition, five pairs of gastric tissues were selected for MeDIP quantitative real-time PCR (MeDIP-qPCR) assay to validate MeDIP-chip observations.
Immunohistochemistry. The streptavidin-peroxidase (SP) method was adopted and performed (7 Evaluation of staining. DNMT expression was assessed by scoring the staining intensity and stained proportion of the cell nucleus. Staining intensity was recorded as negative = 0, light = 1, moderate = 2 or strong = 3. The staining proportion was recorded as 1 (≤25%), 2 (≤50%), 3 (≤75%) or 4 (>75%).
The two values were multiplied for each slide to produce a terminal score. If the score was higher in cancer cells than in matched control cells, this pair of tissues was marked with a '+' (corresponding to cancer cells that expressed elevated DNMT levels). The opposite condition was marked with a '-' (corresponding to cancer cells that expressed reduced DNMT levels). If the scores were equal, the pair was marked with a '0' (corresponding to similar DNMT expression in cancer and control). Terminal scores of 0-3 were defined as negative expression; 4-12 were defined as positive expression. 
Results
Expression of DNMT in gastric SRC tissue. Gastric SRC and matched mucosal tissue expressed DNMT proteins (Fig. 1) . Notably, DNMT protein distribution was observed primarily in the nucleus of cancerous tissue and in the nucleus and cytoplasm of control tissue. DNMT expression in non-cancerous tissue was primarily focused on the proliferating zone of gastric mucosa. DNMTs perform DNA methylation in the nucleus; thus, nuclear staining was investigated. DNMT1 expression was elevated and DNMT3A expression was decreased in gastric SRC when compared with matched control tissue (Fig. 2) . However, expression of other DNMTs did not differ significantly between cancerous and non-cancerous tissue.
Correlation between DNMT expression and clinical characteristics of gastric SRC. According to the TNM classification of malignant tumors, expression of DNMT1 was associated with lymph node metastasis in gastric SRC (Table I) . SRC samples with features of lymph node metastasis and attributes of late TNM classification were found to express DNMT1 protein at (11) BCL11A (25) CARS (12) JUN (26) CDKN1C (13) LYN (27) CDKN2A (14) MYB (28) DLC-1 (15) MYCL1 (29) ING-1 (16) REL (30) OVCA2 (17) SRC (31) RASD1 (18) WNT4 (32) RB-1 (19) WNT9A (32) SYK (20) WNT10A (32) WNT11 (33) KRAS (34) VEGFA (35) RAB6A (36) RAB8A (37) RAB27A (38) RAB32 (39) Hypomethylation only in cancer APAF1 (21) RAB33A (36) CAV2 (22) ABL2 (40) RASSF1 (23) FGF18 (41) EGFL7 (42) FYN (43) MYCNOS (44) RAB3A (45) TRAF2 (46) WNT3A (47) SRC, signet ring cell carcinoma; TSG, tumor suppressor gene; TPG, tumor promotor gene. tissue, whereas other CpG islands and gene promoters were hypermethylated only in matched mucosa tissue (Table II) , indicating that these DNA sequences were hypomethylated only in carcinoma tissue. Following a comprehensive analysis involving separation of genes exhibiting differential DNA methylation in promoters between the carcinoma and control from the genome, and searching for tumor-related genes in these separating genes, gastric SRC was observed to contain hypermethylated and hypomethylated TSGs, oncogenes and tumor-promoter genes (TPGs ; Table III ) .
Validation of the abnormally hypomethylated genes in gastric
SRC by MeDIP-qPCR. ABL2, FGF18, TRAF2, EGFL7 and RAB33A were selected as validation genes. Their primer sequences are presented in Table IV . Using MeDIP-qPCR, the input percentage values of these genes were observed to be significantly lower in SRC than in matched mucosal tissue ( Table V) , indicating that the DNA was abnormally hypomethylated in gastric SRC compared with matched control tissue. This result was in agreement with the MeDIP-chip observations. The input percentage values of these genes the in negative control (non-immune serum) were <0.01.
Discussion
According to the World Health Organization, there are four predominant histological types of gastric adenocarcinoma, papillary, tubular, mucinous and SRC. SRC is characterized by the histological appearance of signet ring cells, a large vacuole full of mucin in the cytoplasm displacing the nucleus to the periphery. This adenocarcinoma originates from the undifferentiated stem cells at the gastric gland neck in gastric lamina propria and accounts for 3.14-29% of gastric cancer (48) . SRC is a poorly differentiated adenocarcinoma with rapid progression and poor prognosis. To date, the etiology of SRC is unclear and therapy is mainly dependent on surgical procedures (SRC is non-responsive to chemotherapy). Epigenetic alterations, including promoter hypermethylation, lead to chromatin remodeling and the silencing of tumor-related genes, and are crucial in tumor progression (49) . DNA methylation is catalyzed mainly by DNMTs, including DNMT1, DNMT2, DNMT3A, DNMT3B and DNMT3L (50) (51) (52) (53) . Previous studies have indicated that overexpression of DNMT may contribute to tumor progression through hypermethylation-mediated TSG inactivation in CpG islands. We hypothesized that overexpression of DNMT also may be detected in SRC.
In the current study, it was observed that gastric SRC and matched mucosal tissue expressed DNMT proteins. DNMT expression in non-cancerous tissue was primarily focused on the proliferating zones of gastric mucosa. An abnormal overexpression of DNMT1 was observed when nuclear staining was taken into consideration in SRC tissue compared with matched mucosal tissue. By contrast, DNMT3A expression in SRC was not significant compared with that in matched controls. For the remaining DNMTs, no expression difference between SRC and control tissue was noted. The observations indicate that overexpression of DNMT in SRC tissue was specific to DNMT1. Table II ). This observation indicated that DNA methylation of the genome increased in SRC compared with matched controls. Notably, in gastric SRC, hypermethylated and hypomethylated TSGs, oncogenes and TPGs were observed. The subsequent MeDIP-qPCR assay validated specific MeDIP-chip results. Tumor-related genes, ABL2, FGF18, TRAF2, EGFL7 and RAB33A, were abnormally hypomethylated in SRC tissue compared with matched controls. This observation is an addition to the traditional DNA methylation theory, which focuses on the hypermethylation of TSG in tumors and indicates that the aberrant DNA methylation pattern of the SRC genome is complex. Similar observations were also demonstrated in liver and pancreatic cancer (54, 55) . Specific tumors exhibit abnormal hypomethylation of TPGs and oncogenes (56, 57) and overexpression of these genes due to hypomethylation, is potentially another epigenetic mechanism for uncontrollable cancer cell proliferation (55) .
In conclusion, gastric SRCs express elevated DNMT1 protein and reduced DNMT3A protein compared with matched gastric mucosa. A difference between genomic DNA methylation between SRC and control (gastric mucosa) samples exists, however, it appears to be complex since it is not limited to hypermethylation of TSGs.
To date, there has been encouraging progression in the understanding of the role of DNA methylation in tumors. However, clinical applications based on DNA methylation theory for diagnosis and treatments of tumors remain scarce. Further investigation is required to investigate the role of DNMT inhibitors, including 5-aza-2'-deoxycytidine, in inhibiting cancer cell proliferation.
